Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes

被引：0
|
作者：
Herbst, Roy S. [1 ]
Stern, Howard [2 ]
Amler, Lukas [2 ]
Otterson, Gregory [3 ]
Lin, Ming [2 ]
O'Connor, Paula [2 ]
Hainsworth, John [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Sarah Cannon Rsrch Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [12] Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC)
    Faoro, L.
    Cohen, E. E.
    Govindan, R.
    Kozloff, M. F.
    Hoffman, P. C.
    Maitland, M. L.
    Verel, K.
    Szeto, L.
    Salgia, R.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [13] A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Miller, V. A.
    Das, A.
    Rossi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [14] A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Miller, V. A.
    O'Connor, P.
    Soh, C.
    Kabbinavar, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [15] Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Herbst, Roy S.
    Ansari, Rafat
    Bustin, Frederique
    Flynn, Patrick
    Hart, Lowell
    Otterson, Gregory A.
    Vlahovic, Gordana
    Soh, Chang-Heok
    O'Connor, Paula
    Hainsworth, John
    LANCET, 2011, 377 (9780): : 1846 - 1854
  • [16] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression
    Reguart, Noemi
    Isla, Dolores
    Cardenal, Felipe
    Cardona, Andres
    Palmero, Ramon
    Moran, Teresa
    Rolfo, Christian Diego
    Nadal, Ernesto Samuel
    Massuti, Tomeu
    Montanes, Ana
    Queralt, Cristina
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S708 - S708
  • [17] Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.
    O'Brien, Mary E. R.
    Eberhardt, Wilfried Ernst Erich
    Altorki, Nasser K.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Cho, Eun Kyung
    Kim, Joo-Hang
    Szczesna, Aleksandra
    Hoffman, Philip C.
    Burghuber, Otto
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Park, Jung Wook
    Shepherd, Frances A.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)
    Edelman, Martin J.
    Wang, Xiaofei
    Hodgson, Lydia
    Cheney, Richard T.
    Baggstrom, Maria
    Sachdev, Thomas
    Gajra, Ajeet
    Bertino, Erin
    Reckamp, Karen
    Molina, Julian
    Schiller, Joan
    Mitchell-Richards, Kisha
    Friedman, Paula
    Ritter, Jon
    Vokes, Everett
    CANCER RESEARCH, 2014, 74 (19)
  • [19] Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
    Thomas, M.
    Reuss, A.
    Fischer, J. R.
    Andreas, S.
    Kortsik, C.
    Grah, C.
    Serke, M. H.
    von Eiff, M.
    Witt, C.
    Kollmeier, J.
    Mueller, E.
    Mueller, L.
    Schenk, M.
    Heine, R.
    Behringer, D. M.
    Schroeder, M.
    Reinmuth, N.
    Schnabel, P.
    Acker, T.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [20] Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
    Kim, Lucia
    Saieg, Mauro
    Di Maio, Massimo
    Gallo, Ciro
    Butts, Charles
    Ciardiello, Fortunato
    Feld, Ronald
    Cheng, Dengxiao
    Gebbia, Vittorio
    Burgio, Marco Angelo
    Alam, Yasmin
    Signoriello, Simona
    Rossi, Antonio
    Leighl, Natasha
    Maione, Paolo
    Morabito, Alessandro
    Liu, Geoffrey
    Tsao, Ming-Sound
    Perrone, Francesco
    Gridelli, Cesare
    ONCOTARGET, 2017, 8 (34) : 57528 - 57536
12345